Don't Be Inspired To Cite Non-Clinical Data Like Clinical Data In Drug Ads, DDMAC Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Inspire Pharmaceuticals gets a letter from FDA's Division of Drug Marketing, Advertising and Communications for a four-page professional journal ad for its bacterial conjunctivitis treatment AzaSite.
You may also be interested in...
Merck's Latest Inspiration Is Bolt-On Acquisition of Inspire Pharma for $430M
The troubled specialty pharma offers Merck immediate revenues in ophthalmology, while the Big Pharma waits for approval of a new drug, Saflutan, for glaucoma and ocular hypertension.
Testimonials Lead To Overbroad Claims, DDMAC Warning Letter Says
Implied efficacy claims from a physician and patients for Testopel testosterone pellets, among many other problems with a series of promotional pieces, draw a warning letter to Slate Pharmaceuticals.
Allergan Lumigan Unsubstantiated Superiority Claims Cited In FDA Warning Letter
The company must send corrective messages regarding the violative sales aid for Lumigan that contains misleading claims regarding the superiority of the ocular therapy, FDA says.